JPWO2020198710A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020198710A5
JPWO2020198710A5 JP2021557651A JP2021557651A JPWO2020198710A5 JP WO2020198710 A5 JPWO2020198710 A5 JP WO2020198710A5 JP 2021557651 A JP2021557651 A JP 2021557651A JP 2021557651 A JP2021557651 A JP 2021557651A JP WO2020198710 A5 JPWO2020198710 A5 JP WO2020198710A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
pharmaceutical composition
halogen
androgen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521824A (ja
JP2022521824A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025539 external-priority patent/WO2020198710A1/en
Publication of JP2022521824A publication Critical patent/JP2022521824A/ja
Publication of JP2022521824A5 publication Critical patent/JP2022521824A5/ja
Publication of JPWO2020198710A5 publication Critical patent/JPWO2020198710A5/ja
Ceased legal-status Critical Current

Links

JP2021557651A 2019-03-28 2020-03-27 アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用 Ceased JP2022521824A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962825450P 2019-03-28 2019-03-28
US62/825,450 2019-03-28
US201962842980P 2019-05-03 2019-05-03
US62/842,980 2019-05-03
US201962857519P 2019-06-05 2019-06-05
US62/857,519 2019-06-05
PCT/US2020/025539 WO2020198710A1 (en) 2019-03-28 2020-03-27 Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof

Publications (3)

Publication Number Publication Date
JP2022521824A JP2022521824A (ja) 2022-04-12
JP2022521824A5 JP2022521824A5 (https=) 2023-04-04
JPWO2020198710A5 true JPWO2020198710A5 (https=) 2023-04-04

Family

ID=72610726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557651A Ceased JP2022521824A (ja) 2019-03-28 2020-03-27 アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用

Country Status (10)

Country Link
US (1) US20220202780A1 (https=)
EP (1) EP3947353A4 (https=)
JP (1) JP2022521824A (https=)
KR (1) KR20210144827A (https=)
CN (1) CN114502539A (https=)
AU (1) AU2020248105A1 (https=)
CA (1) CA3134545A1 (https=)
IL (1) IL286726A (https=)
MX (1) MX2021011826A (https=)
WO (1) WO2020198710A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
AU2020348675B2 (en) 2019-09-16 2025-11-20 Takeda Pharmaceutical Company Limited Azole-fused pyridazin-3(2H)-one derivatives
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
AU2021255723A1 (en) 2020-04-17 2022-12-08 Essa Pharma, Inc. Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
WO2022060969A1 (en) * 2020-09-16 2022-03-24 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
KR20220111673A (ko) * 2021-02-02 2022-08-09 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물
WO2022221661A1 (en) * 2021-04-16 2022-10-20 Essa Pharma, Inc. Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof
CN115340527B (zh) * 2021-05-13 2023-09-15 成都先导药物开发股份有限公司 一种bcl-xl抑制剂及其制备方法和用途
CN113603695B (zh) * 2021-08-05 2022-06-14 青岛恒宁生物科技有限公司 一种取代的嘧啶胺类化合物或其作为农药可接受的盐、组合物及其用途
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
WO2023031371A1 (en) * 2021-09-01 2023-03-09 Janssen Pharmaceutica Nv Combination therapies for metastatic castration-resistant prostate cancer
US20240358701A1 (en) * 2021-09-01 2024-10-31 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN118715210A (zh) * 2022-02-10 2024-09-27 上海奕拓医药科技有限责任公司 雄激素受体活性调节剂及其应用
CN117065033A (zh) * 2022-05-17 2023-11-17 海创药业股份有限公司 一种治疗三阴乳腺癌的联合用药物
WO2024006207A1 (en) * 2022-06-26 2024-01-04 Essa Pharma Inc. An n-terminal domain androgen receptor inhibitor and uses thereof
US11993580B1 (en) 2022-12-02 2024-05-28 Neumora Therapeutics, Inc. Methods of treating neurological disorders
CN121698845A (zh) * 2024-09-12 2026-03-20 青岛普泰科生物医药科技有限公司 一种四氢喹啉类ntd抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2656842T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
WO2013028572A1 (en) * 2011-08-19 2013-02-28 British Columbia Cancer Agency Branch Fluorinated bisphenol ether compounds and methods for their use
PT2872482T (pt) * 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
JP6884100B2 (ja) * 2015-01-13 2021-06-09 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法
US10980806B2 (en) * 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US20170298033A1 (en) * 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
LT3474841T (lt) * 2016-06-22 2022-06-10 Ellipses Pharma Ltd Ar+ krūties vėžio gydymo būdai
MX2021004427A (es) * 2018-10-18 2021-11-12 Univ British Columbia Moduladores del receptor de andrógenos y métodos para su uso.

Similar Documents

Publication Publication Date Title
JPWO2020198710A5 (https=)
KR102246652B1 (ko) 암 치료용 화합물
Roth et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)
Schade et al. Synthesis and SAR of b-annulated 1, 4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling
ES2374451T3 (es) Bencimidazoles sustituidos como inhibidores de quinasa.
JP5773873B2 (ja) ヘッジホッグ経路関連障害の治療のためのスムースンド拮抗作用
AU2013266110C1 (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP2010514689A5 (https=)
JPWO2020081999A5 (https=)
JP2013518909A (ja) アロステリックキナーゼ阻害が関係する治療方法および組成物
JP2018100297A5 (https=)
JP2005511608A5 (https=)
RU2009114414A (ru) Способ лечения рака, несущего мутации egfr
JP2014518544A5 (https=)
JP2010503717A5 (https=)
RS51807B (sr) Kombinacije za lečenje bolesti koje obuhvataju ćelijsku proliferaciju
TW202104212A (zh) 以雜環化合物作為激酶抑制劑的治療用途
JP7197370B2 (ja) がんの予防および/または治療のための化合物、組成物および方法
KR20180088457A (ko) 벤조티오펜-기반 선택적 에스트로겐 수용체 하향조절제
RU2014154009A (ru) Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
Li et al. Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3-morpholinopropoxy) quinazolin-4-ylthio]-[1, 3, 4] thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo
JP7849141B2 (ja) がんの治療のためのnox阻害剤の使用
CA3023202A1 (en) Combination treatment of cancer
JP2019507114A5 (https=)
JP2020524152A (ja) 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法